Cytokine zalpha11 Ligand
AssigneeZymoGenetics, Inc.
InventorsJulia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
Life of this patent
Estimating the term…
Abstract
The present invention relates to zalpha11 Ligand polynucleotide and polypeptide molecules. The zalpha11 Ligand is a novel cytokine. The polypeptides may be used within methods for stimulating the proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
Claims23
An isolated polypeptide comprising a sequence of amino acid residues that is at least 90% identical to residues 41 (Gln) to 148 (Ile) as shown in SEQ ID NO:
- 2, wherein the residue at position 44 is Asp, the residue at position 47 is Asp and the residue at position 135 is Glu, wherein the polypeptide binds a zalpha11 receptor as shown in SEQ ID NO:
- 115.
An isolated polypeptide comprising a sequence of amino acid residues as shown in SEQ ID NO:
- 2 from residue 32 (Gln) to residue 162 (Ser).
An isolated polypeptide comprising at least 14 contiguous amino acid residues of SEQ ID NO:
- 2 or SEQ ID NO:
- 56, wherein said polypeptide stimulates an antigenic response in a mammal.
An isolated polypeptide comprising a sequence of amino acid residues that is at least 90% identical to amino acid residue 32 (Gln) to amino acid residue 162 (Ser) as shown in SEQ ID NO:
- 2, wherein the polpeptide binds a zalpha11 receptor as shown in SEQ ID NO:
- 115.
An isolated polypeptide comprising a sequence of amino acid residues that is at least 95% identical to amino acid residue 32 (Gln) to amino acid residue 162 (Ser) as shown in SEQ ID NO:
- 2, wherein the polypeptide binds a zalpha11 receptor as shown in SEQ ID NO:
- 115.
An isolated polypeptide comprising a sequence of amino acid residues from amino acid residue 41 (Gln) to amino acid residue 145 (Gln) as shown in SEQ ID NO:
- 2, wherein the polypeptide binds a zalpha11 receptor as shown in SEQ D NO:115.
An isolated polypeptide comprising a sequence of amino acid residues from amino acid residue 32 (Gln) to amino acid residue 145 (Gln) as shown in SEQ ID NO:
- 2, wherein the polypeptide binds a zalpha11 receptor as shown in SEQ ID NO:
- 115.
An isolated polypeptide comprising a sequence of amino acid residues that is at least 90% identical to amino acid residue 41 (Gln) to amino acid residue 162 (Ser) as shown in SEQ ID NO:
- 2, wherein amino acid residue 145 is Asp and amino acid residue 148 is Asp, and wherein the polypeptide binds a zalpha11 receptor as shown in SEQ ID NO:
- 115.
An isolated polypeptide comprising a sequence of amino acid residues that is at least 90% identical to amino acid residue 32 (Gln) to amino acid residue 162 (Ser) as shown in SEQ ID NO:
- 2, wherein amino acid residue 145 is Asp and amino acid residue 148 is Asp, and wherein the polypeptide binds a zalpha11 receptor as shown in SEQ I) NO:115.
An isolated polypeptide comprising a sequence of amino acid residue that is at least 90% identical to a sequence as shown in SEQ ID NO:
- 2, from amino acid residue 41 (Gln) to amino acid residue 145, wherein residue 145 is Asp not Gln, and wherein the polypeptide binds a zalpha11 receptor as shown in SEQ ID NO:115.
An isolated polypeptide comprising a sequence of amino acid residues as shown in SEQ ID NO:
- 56 from residue 23 (Gln) to residue 146 (Ser), wherein the polypeptide binds a zalpha11 receptor as shown in SEQ ID NO:
- 115.
An isolated polypeptide comprising at least 14 contiguous amino acid residues selected from the group consisting of:
- (a) amino acid residues 41-56 of SEQ ID NO:
- 2;
- (b) amino acid residues 68-84 of SEQ ID NO;
- 2;
- (c) amino acid residues 92-105 of SEQ ID NO:
- 2;
- and
- (d) amino acid residues 135-148 of SEQ ID NO:
- 2, wherein amino acid residue 145 is Asp and amino acid residue 148 is Asp, and wherein said polypeptide stimulates an antigenic response in a mammal.
Dependencies are inferred from the claim text.